Value for patients has always been the focus of biotech – a new order is needed to ensure they never miss out on innovations

28 July 2022

Amicus Therapeutics (Nasdaq: FOLD) chairman and chief executive John Crowley and the company's general manager for the UK and Ireland, Charlie Galvin, provide an Expert View on the importance of the pact in ensuring the biotech industry meets its commitments to share the value of innovation with patients, protect health system budgets, and ensure sustainable access.

The UK sits at the fore of a golden age of medicine. Conditions which only a decade ago spelled death can now be treated, allowing people living with a rare disease to be diagnosed, treated and potentially even cured in a way that was not possible before.

This is, of course, why we in the biotech sector do what we do – we innovate to bring life-changing treatments to patients who need them.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK